The Efficacy of Continuous Versus Intermittent Celecoxib Treatment in Osteoarthritis Patients with Body Mass Index ≥30 and <30 kg/m2

Table 3: Number of Flare Events Per Time of Exposure to Study Medication^a

	BMI <30 kg/m²			BMI ≥30 kg/m²
	Continuous Use Celecoxib 200 mg qd	Intermittent Use Celecoxib 200 mg qd	p Value	Continuous Use Celecoxib 200 mg qd	Intermittent Use Celecoxib 200 mg qd	p Value
ITT population, n	209	205		222	222
No. of flare events per month, mean (SD)	0.55 (0.78)	0.88 (0.86)	<0.0001	0.54 (0.69)	0.97 (1.13)	<0.0001
Median	0.38	0.63		0.36	0.71
Range	0.00-7.50	0.00-4.29		0.00-4.29	0.00-9.40
FmITT population, n	146	121		153	151
No. of flare events per month, mean (SD)	0.51 (0.88)	0.91 (1.01)	0.0008	0.47 (0.74)	0.98 (1.32)	<0.0001
Median	0.20	0.57		0.19	0.55
Range	0.00-7.50	0.00-4.29		0.00-4.29	0.00-9.40

^a Time of exposure is the time in months from the first dose of double-blind study medication at the beginning of Period III to the last dose of study medication. Patients may have more than one flare.

ITT, intent-to-treat; FmITT: flare-modified ITT.